Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
18 Julho 2023 - 5:05PM
Business Wire
– Conference Call and Webcast to Follow at 5:00
p.m. ET / 2:00 p.m. PT –
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second
quarter 2023 financial results will be released on Tuesday, August
1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT,
Exelixis management will host a conference call and webcast to
discuss the results and provide a general business update. Access
to the event is available via the Internet from the company’s
website.
To access the conference call, please register using this link.
Upon registration, a dial-in number and unique PIN will be provided
to join the call. To access the live webcast link, log onto
www.exelixis.com and proceed to the News & Events / Event
Calendar page under the Investors & Media heading. Please
connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download
that may be required to listen to the webcast. A webcast replay of
the conference call will also be archived on www.exelixis.com for
one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating
next-generation medicines and regimens at the forefront of cancer
care. Powered by bi-coastal centers of discovery and development
excellence, we are rapidly evolving our product portfolio to target
an expanding range of tumor types and indications with our
clinically differentiated pipeline of small molecules,
antibody-drug conjugates and other biotherapeutics. This
comprehensive approach harnesses decades of robust investment in
our science and partnerships to advance our investigational
programs and extend the impact of our flagship commercial product,
CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific
pursuit to create transformational treatments that give more
patients hope for the future. For information about the company and
its mission to help cancer patients recover stronger and live
longer, visit www.exelixis.com, follow @ExelixisInc on Twitter,
like Exelixis, Inc. on Facebook and follow Exelixis on
LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are
registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718950128/en/
Investors Contact: Varant Shirvanian Associate Director,
Investor Relations Exelixis, Inc. 650-837-8194
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Exelixis (NASDAQ:EXEL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024